Reliable in the immunosuppressed
The T-SPOT.TB test is reliable, even in challenging testing populations, such as immunosuppressed patients. The test is based on a simplified ELISPOT method and is the most accurate test available for the detection of MTB with a sensitivity of 98.8%2. Immunosuppressed individuals face a higher risk of contracting tuberculosis (TB) and a higher risk of latent tuberculosis infection (LTBI) becoming active.9
Various organisations, including the World Health Organization have identified the following groups of people as being at high-risk for developing active TB disease once infected with Mycobacterium tuberculosis (MTB)1:
People living with diabetes in the world
Cases of Crohn’s disease and inflammatory bowel disease globally
Global population who are living with rheumatoid arthritis
People worldwide living with HIV/AIDS
Population worldwide who are affected by chronic kidney disease
Why are the immunosuppressed at risk?
There are many reasons for the increased risk faced by those with suppressed immune systems. These include:
- Risk of progression from LTBI to active TB can be much higher than in a healthy population9
- TB infection can increase the progression of comorbid conditions, such as HIV15
- Management of TB can be complicated by drug interactions and cumulative toxicities1
- Reduced T cell counts and functionality can make it difficult for some tests to detect an immune response to MTB infection16
The T-SPOT.TB test is the only IGRA available that is normalised for both cell number and culture conditions. The test standardises the number of cells and removes serum factors that could adversely affect the test result, making it the most sensitive and most specific test for TB infection2,3. You can quickly and reliably diagnose and treat TB infection in all patient groups, including the immunosuppressed4.
The T-SPOT.TB test is designed to maintain performance, even in the immunosuppressed2
The reliability of the T-SPOT.TB test design, which includes washing and standardising the number of cells in each patient specimen, is supported by clinical data obtained even in challenging patient populations. The cell enumeration technology in the proprietary T-SPOT.TB test therefore will allow clinicians to confidently screen and detect TB infection.2
Patient populations can vary, but your TB test results should not. The
T-SPOT.TB test is accurate across patient populations.
Accurate across patient populations4
Only TB test with sensitivity and specificity > 98%2
- Sensitivity: 98.8%
- Specificity: 99.1%
High test accuracy around result cut-off due to regulatory approved borderline zone – helping to prevent inappropriate therapy2,5